



Claire Aldridge, PhD

Chief Strategy Officer

Form Bio

Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease.

She currently serves as Director of Biotech for Capital Factory, the center of gravity for entrepreneurs in Texas. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the Chair of the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. She also sits on the Product Development Advisory Committee for CPRIT, the \$6B Texas effort to help Texans conquer cancer through research, prevention and commercialization.

Dr. Aldridge brings more than 25 years' experience facilitating the translation of scientific discoveries into patient and commercial benefits and has leveraged her training to be a liaison between scientists and non-scientists. Her roles have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; and biotech and life science investing through venture capital.

Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.